DE60336576D1 - Hemmer der akt aktivität - Google Patents

Hemmer der akt aktivität

Info

Publication number
DE60336576D1
DE60336576D1 DE60336576T DE60336576T DE60336576D1 DE 60336576 D1 DE60336576 D1 DE 60336576D1 DE 60336576 T DE60336576 T DE 60336576T DE 60336576 T DE60336576 T DE 60336576T DE 60336576 D1 DE60336576 D1 DE 60336576D1
Authority
DE
Germany
Prior art keywords
compounds
hemmer
activity
act activity
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336576T
Other languages
German (de)
English (en)
Inventor
Mark E Duggan
Craig W Lindsley
Zhijian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of DE60336576D1 publication Critical patent/DE60336576D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60336576T 2002-10-30 2003-10-24 Hemmer der akt aktivität Expired - Lifetime DE60336576D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42230702P 2002-10-30 2002-10-30
PCT/US2003/034007 WO2004041162A2 (en) 2002-10-30 2003-10-24 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
DE60336576D1 true DE60336576D1 (de) 2011-05-12

Family

ID=32312489

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336576T Expired - Lifetime DE60336576D1 (de) 2002-10-30 2003-10-24 Hemmer der akt aktivität

Country Status (8)

Country Link
US (1) US7399764B2 (https=)
EP (1) EP1558586B1 (https=)
JP (1) JP2006507299A (https=)
AT (1) ATE503483T1 (https=)
AU (1) AU2003284981B2 (https=)
CA (1) CA2501365C (https=)
DE (1) DE60336576D1 (https=)
WO (1) WO2004041162A2 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1620095A4 (en) * 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN1809536A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
ATE461179T1 (de) * 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
AU2005233584B2 (en) * 2004-04-09 2010-12-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2005233569B2 (en) * 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7544677B2 (en) * 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
EP1814883A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US8008317B2 (en) 2005-06-10 2011-08-30 Merck Sharp & Dohme Corp. Inhibitors of akt activtiy
WO2007087246A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) * 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
WO2008070823A2 (en) * 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2726317A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2299825B1 (en) * 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
AU2010213192A1 (en) * 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) * 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011094288A1 (en) * 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2598505B1 (en) * 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
KR101470115B1 (ko) * 2013-01-09 2014-12-05 동국대학교 산학협력단 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
CN115003303B (zh) 2019-12-17 2024-03-08 默沙东公司 Prmt5抑制剂
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431262A (en) * 1968-03-26 1969-03-04 American Home Prod Pyrazolo quinoxalines
JPS5416497A (en) * 1977-07-08 1979-02-07 Nippon Soda Co Ltd Aminooxopyrrolopyrazine compounds and their preparation
TW251284B (https=) 1992-11-02 1995-07-11 Pfizer
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
RO115522B1 (ro) 1995-02-02 2000-03-30 Smithkline Beecham P.L.C. Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament
US5972937A (en) 1995-02-02 1999-10-26 Smithkline Beecham P.L.C. Heterocyclic compounds possessing 5HT2C receptor antagonist activity
ATE274053T1 (de) 1995-11-16 2004-09-15 Novartis Pharma Gmbh Methode zur identifizierung von verbindungen die mit rac proteine kinase interagieren
US20020127214A1 (en) * 1995-11-16 2002-09-12 Hemmings Brian Arthur RAC-protein kinase as therapeutic agent or in diagnostics
US20020132326A1 (en) * 1995-12-15 2002-09-19 Hemmings Brian A. Process for activating a kinase
GB9525702D0 (en) 1995-12-15 1996-02-14 Ciba Geigy Ag Process for activating a kinase
EP0868195A2 (en) 1995-12-20 1998-10-07 Medical Research Council Control of protein synthesis, and screening method for agents
WO1997049704A1 (en) 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
US6329375B1 (en) * 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
WO1999042461A1 (en) 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
JP2002284684A (ja) * 2001-01-16 2002-10-03 Japan Science & Technology Corp チエノイソキノロン含有抗菌抗ウィルス剤および抗腫瘍剤
JP2002220338A (ja) * 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するＣｄｋ４及び／又はＣｄｋ６阻害剤
US20040116433A1 (en) * 2002-04-08 2004-06-17 Owens Andrew Pate Inhibitors of akt activity
WO2002083675A2 (en) * 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2002083140A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US7034026B2 (en) 2001-04-10 2006-04-25 Merck & Co., Inc. Inhibitors of Akt activity
US20040106540A1 (en) * 2001-04-10 2004-06-03 Barnett Stanley F Method of treating cancer
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
EP1496981A2 (en) 2002-04-08 2005-01-19 Merck & Co., Inc. Method of treating cancer
EP1494675A4 (en) 2002-04-08 2006-07-19 Merck & Co Inc HEMMER OF ACT ACTIVITY
CA2481241C (en) 2002-04-08 2010-07-27 Merck & Co., Inc. Fused quinoxaline derivatives as inhibitors of akt activity
CA2480880C (en) * 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Also Published As

Publication number Publication date
ATE503483T1 (de) 2011-04-15
EP1558586B1 (en) 2011-03-30
AU2003284981B2 (en) 2009-05-28
EP1558586A4 (en) 2007-06-27
US7399764B2 (en) 2008-07-15
US20050288294A1 (en) 2005-12-29
JP2006507299A (ja) 2006-03-02
CA2501365A1 (en) 2004-05-21
WO2004041162A3 (en) 2004-07-29
EP1558586A2 (en) 2005-08-03
WO2004041162A2 (en) 2004-05-21
AU2003284981A1 (en) 2004-06-07
CA2501365C (en) 2011-05-31

Similar Documents

Publication Publication Date Title
DE60336576D1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
DE602004023838D1 (de) Hemmer der akt aktivität
WO2004096130A3 (en) Inhibitors of akt activity
ATE512957T1 (de) Hemmer der akt aktivität
DE602005026509D1 (de) Hemmer der akt aktivität
ATE400274T1 (de) Hemmstoffe der akt aktivität
RU2394826C2 (ru) Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы
WO2003086279A3 (en) Inhibitors of akt activity
WO2006036395A3 (en) Inhibitors of akt activity
CA2480800A1 (en) Inhibitors of akt activity
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1678166T3 (da) Proteinkinaseinhibitorer
TW200611907A (en) Fused heterocyclic compound
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
WO2006065601A8 (en) Inhibitors of akt activity
BRPI0413233A (pt) novos compostos
MX2010000658A (es) Derivados de pirimidina 934.
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
MXPA05009151A (es) Inhibidores de cinasa heterociclica.

Legal Events

Date Code Title Description
R081 Change of applicant/patentee

Ref document number: 1558586

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1558586

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213